CA3155864A1 - Antagonists of the muscarinic acetylcholine receptor m4 - Google Patents
Antagonists of the muscarinic acetylcholine receptor m4Info
- Publication number
- CA3155864A1 CA3155864A1 CA3155864A CA3155864A CA3155864A1 CA 3155864 A1 CA3155864 A1 CA 3155864A1 CA 3155864 A CA3155864 A CA 3155864A CA 3155864 A CA3155864 A CA 3155864A CA 3155864 A1 CA3155864 A1 CA 3155864A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pyran
- tetrahydro
- pyrrol
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910863P | 2019-10-04 | 2019-10-04 | |
| US62/910,863 | 2019-10-04 | ||
| PCT/US2020/053942 WO2021067696A1 (en) | 2019-10-04 | 2020-10-02 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3155864A1 true CA3155864A1 (en) | 2021-04-08 |
Family
ID=75337550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3155864A Pending CA3155864A1 (en) | 2019-10-04 | 2020-10-02 | Antagonists of the muscarinic acetylcholine receptor m4 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12319701B2 (enExample) |
| EP (1) | EP4037677B1 (enExample) |
| JP (1) | JP7572734B2 (enExample) |
| AU (1) | AU2020358000B2 (enExample) |
| CA (1) | CA3155864A1 (enExample) |
| ES (1) | ES3057371T3 (enExample) |
| WO (1) | WO2021067696A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| CA3180717A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240174655A1 (en) * | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| WO2022261427A1 (en) * | 2021-06-11 | 2022-12-15 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
| CA3226995A1 (en) | 2021-07-21 | 2023-01-26 | Nico Therapeutics, Inc. | Annulated pyridazine compound |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| EA018128B1 (ru) | 2006-01-23 | 2013-05-30 | Амген Инк. | Модуляторы аурора киназы, способы их получения и их применение |
| EP2038289A2 (en) * | 2006-04-21 | 2009-03-25 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
| WO2011149995A1 (en) * | 2010-05-25 | 2011-12-01 | Abbott Laboratories | Novel substituted octahydrocyclopenta [c]pyrrol-4-amines as calcium channel blockers |
| WO2015027204A1 (en) * | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| BR112018016689A2 (pt) * | 2016-02-16 | 2019-02-12 | Univ Vanderbilt | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m1 |
| PL3507289T3 (pl) | 2016-09-02 | 2021-01-25 | Suven Life Sciences Limited | Dodatnie allosteryczne modulatory receptora muskarynowego m1 |
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| ES2982890T3 (es) * | 2017-10-31 | 2024-10-18 | Univ Vanderbilt | Antagonistas del receptor muscarínico de acetilcolina M4 |
| CA3090130A1 (en) * | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2021119254A1 (en) | 2019-12-10 | 2021-06-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| AU2020402978A1 (en) | 2019-12-10 | 2022-06-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| US20230183219A1 (en) | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| CA3180717A1 (en) | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| CA3199786A1 (en) | 2020-11-18 | 2022-05-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CN116669737A (zh) | 2020-12-22 | 2023-08-29 | 范德堡大学 | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 |
| JP2024500880A (ja) | 2020-12-22 | 2024-01-10 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| US20240174655A1 (en) | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240228468A1 (en) | 2021-04-05 | 2024-07-11 | Vanderbilt University | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders |
| WO2022261427A1 (en) | 2021-06-11 | 2022-12-15 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
-
2020
- 2020-10-02 US US17/766,341 patent/US12319701B2/en active Active
- 2020-10-02 ES ES20873262T patent/ES3057371T3/es active Active
- 2020-10-02 JP JP2022520473A patent/JP7572734B2/ja active Active
- 2020-10-02 AU AU2020358000A patent/AU2020358000B2/en active Active
- 2020-10-02 EP EP20873262.8A patent/EP4037677B1/en active Active
- 2020-10-02 WO PCT/US2020/053942 patent/WO2021067696A1/en not_active Ceased
- 2020-10-02 CA CA3155864A patent/CA3155864A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022550459A (ja) | 2022-12-01 |
| EP4037677A4 (en) | 2023-05-03 |
| EP4037677B1 (en) | 2025-09-24 |
| US20240083907A1 (en) | 2024-03-14 |
| WO2021067696A1 (en) | 2021-04-08 |
| US12319701B2 (en) | 2025-06-03 |
| AU2020358000B2 (en) | 2026-05-28 |
| AU2020358000A1 (en) | 2022-04-07 |
| EP4037677A1 (en) | 2022-08-10 |
| JP7572734B2 (ja) | 2024-10-24 |
| ES3057371T3 (en) | 2026-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023202086B2 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
| EP4037677B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| US11225484B2 (en) | Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4 | |
| WO2019126559A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP4267569B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2021216951A1 (en) | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2022216655A1 (en) | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders | |
| EP4196473B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| US12630540B2 (en) | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-LAMBDA6-sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor M4 antagonists for the treatment of neurodegenerative disorders | |
| CA3180717A1 (en) | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2019152809A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| US20230150986A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP4247803A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| CA3241298A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20240816 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240910 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241112 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250414 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250819 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250819 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250908 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251229 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260120 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260120 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260601 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260602 |